ATE362360T1 - Hemmer des phosphattransports - Google Patents

Hemmer des phosphattransports

Info

Publication number
ATE362360T1
ATE362360T1 AT02806234T AT02806234T ATE362360T1 AT E362360 T1 ATE362360 T1 AT E362360T1 AT 02806234 T AT02806234 T AT 02806234T AT 02806234 T AT02806234 T AT 02806234T AT E362360 T1 ATE362360 T1 AT E362360T1
Authority
AT
Austria
Prior art keywords
phosphate transport
transport inhibitors
lower alkyl
substituted
alkyl group
Prior art date
Application number
AT02806234T
Other languages
English (en)
Inventor
Thomas Jozefiak
Cecilia Bastos
Andrew Papoulis
Stephen Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE362360T1 publication Critical patent/ATE362360T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02806234T 2001-12-26 2002-12-24 Hemmer des phosphattransports ATE362360T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34466001P 2001-12-26 2001-12-26
US37164902P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
ATE362360T1 true ATE362360T1 (de) 2007-06-15

Family

ID=26994039

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02806234T ATE362360T1 (de) 2001-12-26 2002-12-24 Hemmer des phosphattransports
AT06077276T ATE464905T1 (de) 2001-12-26 2002-12-24 Phosphattransporthemmer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06077276T ATE464905T1 (de) 2001-12-26 2002-12-24 Phosphattransporthemmer

Country Status (7)

Country Link
US (2) US7119120B2 (de)
EP (2) EP1465638B1 (de)
JP (2) JP4610900B2 (de)
AT (2) ATE362360T1 (de)
AU (1) AU2002367396A1 (de)
DE (2) DE60220188T2 (de)
WO (1) WO2003057225A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
NZ538513A (en) * 2002-09-05 2007-02-23 Neurosearch As Diarylurea derivatives and their use as chloride channel blockers
EP1398029A1 (de) * 2002-09-10 2004-03-17 LION Bioscience AG 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US7220406B2 (en) 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
DE10257357A1 (de) * 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
AU2005250336B2 (en) * 2004-04-20 2011-06-09 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
WO2006077901A1 (ja) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf発現阻害剤
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20080069860A1 (en) * 2005-08-17 2008-03-20 Allison Wren Hyperphosphatemia in domestic animals: compositions and methods of treatment
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
GB0526255D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
EP2164329A4 (de) * 2007-05-08 2010-11-17 Burnham Inst Medical Research Nicht gewebespezifische alkali-phosphatase-hemmer und ihre verwendung zur behandlung von gefässverkalkungen
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
US20110251220A1 (en) * 2008-06-03 2011-10-13 Acikgoez Oezlem Pharmaceutical compositions comprising gamma secretase modulators
BR122019022071B8 (pt) 2008-06-09 2021-07-27 Univ Muenchen Ludwig Maximilians composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit
CA2729767A1 (en) * 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2746832C (en) 2009-01-26 2017-10-03 Cytochroma Inc. Phosphate management with small molecules
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
RU2566757C2 (ru) * 2010-03-05 2015-10-27 Дуофос Арилфторфосфатные ингибиторы кишечного апикального мембранного натрий/фосфатного котранспорта
JP5993368B2 (ja) 2010-05-12 2016-09-14 スペクトラム ファーマシューティカルズ インコーポレイテッド 炭酸ランタン水酸化物、ランタンオキシカルボネートならびにその製造および使用方法
JP5827328B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012006473A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590965B1 (de) * 2010-07-07 2016-04-20 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2595988B1 (de) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclische verbindungen und verfahren zu ihrer herstellung
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
EP2705035B1 (de) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclische pyrazolsulfonamidverbindungen sowie verfahren und herstellung zu ihrer herstellung
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2887964B1 (de) 2012-08-21 2019-07-03 Ardelyx, Inc. Verbindungen und verfahren zur hemmung von nhe-vermitteltem antiport bei der behandlung von erkrankungen im zusammenhang mit flüssigkeitsretention oder salzüberlastung und erkrankungen des gastrointestinaltraktes
EP2917197B1 (de) 2012-11-05 2019-06-05 Zafgen, Inc. Tricyclische verbindungen und verfahren zur herstellung und verwendung davon
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
WO2014071369A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
SI2983667T1 (sl) 2013-04-12 2019-09-30 Ardelyx, Inc. Spojine za vezavo NHE3 in metode za zaviranje transporta fosfata
CN103467452B (zh) * 2013-09-11 2015-11-18 陕西理工学院 一种苯甲酰胺类化合物及其应用
CN106008360B (zh) * 2016-08-11 2018-10-16 华南农业大学 一种对氨基苯磺酰咪唑及其制备方法
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
WO2019028343A1 (en) * 2017-08-03 2019-02-07 Georgetown University SMALL MOLECULE INHIBITORS OF SLC25A1
BR112020014559A2 (pt) 2018-01-17 2020-12-08 Migal - Galilee Research Institute Ltd. Inibidores inovadores da via metabólica da metionina
EP4324329A3 (de) 2018-01-17 2024-04-17 Migal Galilee Research Institute Ltd. Neue methionin-stoffwechselweghemmer
WO2019179436A1 (zh) * 2018-03-20 2019-09-26 成都海创药业有限公司 一种酰胺类化合物及其在治疗癌症中的用途
WO2019232384A1 (en) * 2018-06-01 2019-12-05 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
MX2021012250A (es) 2019-04-11 2022-01-18 Angion Biomedica Corp Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.
US20220323389A1 (en) * 2019-08-26 2022-10-13 Georgetown University Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL307265A1 (en) 1992-07-28 1995-05-15 Rhone Poulenc Rorer Ltd Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995018097A1 (fr) 1993-12-27 1995-07-06 Eisai Co., Ltd. Derive de l'acide anthranilique
BR9611210A (pt) 1995-10-23 1999-12-28 Zymogenetics Inc Composições e processos para tratamento de condições ósseas deficitárias
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
JP2001513503A (ja) 1997-08-06 2001-09-04 スミスクライン・ビーチャム・コーポレイション 心臓血管系の疾病の治療に用いられるマクロファージスカベンジャー受容体アンタゴニスト
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
JP3972163B2 (ja) * 1999-06-18 2007-09-05 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
CO5190714A1 (es) 1999-07-20 2002-08-29 Smithkline Beecham Corp Inhibidores del transporte de fosfato
US20030212074A1 (en) 2000-05-02 2003-11-13 Dimitri Gaitanopoulos Phosphate transport inhibitors
JP2003533477A (ja) 2000-05-12 2003-11-11 スミスクライン・ビーチャム・コーポレイション リン酸輸送阻害剤
WO2002028353A2 (en) * 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors

Also Published As

Publication number Publication date
WO2003057225A3 (en) 2004-04-08
EP1815860B1 (de) 2010-04-21
US7119120B2 (en) 2006-10-10
ATE464905T1 (de) 2010-05-15
EP1815860A2 (de) 2007-08-08
JP2005514413A (ja) 2005-05-19
DE60220188D1 (de) 2007-06-28
DE60220188T2 (de) 2008-01-24
WO2003057225A2 (en) 2003-07-17
JP2010132674A (ja) 2010-06-17
US20070021509A1 (en) 2007-01-25
US20040019113A1 (en) 2004-01-29
JP4610900B2 (ja) 2011-01-12
EP1815860A3 (de) 2007-11-21
EP1465638A2 (de) 2004-10-13
EP1465638B1 (de) 2007-05-16
DE60236117D1 (de) 2010-06-02
AU2002367396A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
ATE362360T1 (de) Hemmer des phosphattransports
DK0931788T3 (da) Metalloproteasehæmmere
DE69221794D1 (de) 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
NO20034595L (no) Kinolin- og kinazolinderivater med azolylgruppe
DK0695293T3 (da) 10,11-methanodibenzosuberanderivater anvendt som kemosensibiliserende midler
IT1290823B1 (it) Idrossifeniltriazine
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
ES2126075T3 (es) Derivados biciclicos nitrogenados como inhibidores de la propil-endopeptidasa.
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
FI20001593A0 (fi) Comt-entsyymiä inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
ATE296827T1 (de) Heteropolycyclische inhibitoren
MY101917A (en) Biocidal mixture
ES2191763T3 (es) Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.
DE69941307D1 (de) Prenyl transferasinhibitoren
ATE413174T1 (de) Nicht-nucleoside revers-transcriptase inhibitoren
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ATE430476T1 (de) Schlammbehandlung
EA199800931A1 (ru) Способ получения ингибиторов фосфодиэстеразы iv
MXPA03005556A (es) Derivados de 1,1-dioxo-1,2-benzotiacina-3-carboxamidas, metodo para prepararlos y composiciones farmaceuticas que los contienen.
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
DE60108873D1 (de) Nicht-antibakterielle tetrazykline als anti-pilz medikamente
HUP0302576A2 (hu) Fungicid keverékek

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties